Panel Discussion: Liquid Biopsy at the Point of Care: Making ctDNA Actionable for Treatment Selection
- Where We Are Today: Real‑world use of liquid biopsy across biomarker selection, resistance detection at progression, and treatment response/MRD monitoring
- What’s Holding Adoption Back (And Where it’s Worst): Evidence and guideline clarity, reimbursement and logistics, workflow integration, and report interpretability, with a focus on medically underserved settings and populations
- How We Move the Needle: Oncologist perspectives on what would most increase willingness and ability to order, interpret, and act on results, with practical actions for biopharma, diagnostics, and health systems